Stereotactic Body Radiotherapy (SBRT) for High-risk Central Pulmonary Metastases

Overview

Journal Radiat Oncol

Publisher Biomed Central

Specialties Oncology
Radiology

Date 2016 Feb 28

PMID 26920142

Citations 21

Authors

Jonathan W Lischalk

Ryan M Malik

Sean P Collins

Brian T Collins

Ismael A Matus

Eric D Anderson

Affiliations

Soon will be listed here.

Abstract

Background And Purpose: Radiotherapy of central lung tumors carries a higher risk of treatment-related toxicity and local failure. In the era of aggressive oligometastic management the exploration of the proper dose-fractionation for metastatic central lung tumors is essential.

Materials And Methods: Patients diagnosed with high-risk metastatic lesions of the central pulmonary tree comprised this single-institutional retrospective analysis. "High-risk" central pulmonary lesions were defined as those with abutment and/or invasion of the mainstem bronchus. All patients were treated using the CyberKnife SBRT system in 5 fractions to a total dose of 35 or 40 Gy.

Results: Twenty patients were treated from 2008 to 2011 at Georgetown University Hospital. At a median follow up of 19 months, 1-year Kaplan-Meier local control and overall survival was 70 and 75 %, respectively. Late grade 2 or higher atelectasis was the most common treatment-related toxicity and was significantly associated with maximum dose to the mainstem bronchus. Gross endobronchial involvement was associated with significantly lower overall survival.

Conclusions: Five-fraction SBRT to a total dose of 35 or 40 Gy appears to be a safe and effective management strategy for high-risk central pulmonary metastatic lesions, though care should be taken to limit the maximum point dose to the mainstem bronchus.

Citing Articles

The First Reported Case of Treating the Ultra-Central Thorax With Cone Beam Computed Tomography-Guided Stereotactic Adaptive Radiotherapy (CT-STAR).

Zhao S, Beckert R, Zhao X, Laugeman E, Robinson C, Vlacich G Cureus. 2024; 16(6):e62906.

PMID: 39040774 PMC: 11262774. DOI: 10.7759/cureus.62906.

Accelerated Hypofractionated Magnetic Resonance Guided Adaptive Radiation Therapy for Ultracentral Lung Tumors.

La Rosa A, Mittauer K, Bassiri N, Rzepczynski A, Chuong M, Yarlagadda S Tomography. 2024; 10(1):169-180.

PMID: 38250959 PMC: 10820032. DOI: 10.3390/tomography10010013.

Ten fraction hypofractionated stereotactic body radiotherapy for the management of ultracentral lung tumors: a retrospective analysis of dosimetry, outcomes, and toxicity.

Rock C, Sood S, Cao Y, Shelton S, Chen R, Wang F Radiat Oncol. 2023; 18(1):128.

PMID: 37533092 PMC: 10394937. DOI: 10.1186/s13014-023-02298-1.

Approaches to the Management of Metastatic Adenoid Cystic Carcinoma.

Lee R, Wai K, Chan J, Ha P, Kang H Cancers (Basel). 2022; 14(22).

PMID: 36428790 PMC: 9688467. DOI: 10.3390/cancers14225698.

Stereotactic body radiation therapy for metastatic lung metastases.

Kimura T, Fujiwara T, Kameoka T, Adachi Y, Kariya S Jpn J Radiol. 2022; 40(10):995-1005.

PMID: 36097233 PMC: 9529709. DOI: 10.1007/s11604-022-01323-9.

References

Mangona V, Aneese A, Marina O, Hymas R, Ionascu D, Robertson J . Toxicity after central versus peripheral lung stereotactic body radiation therapy: a propensity score matched-pair analysis. Int J Radiat Oncol Biol Phys. 2014; 91(1):124-32. DOI: 10.1016/j.ijrobp.2014.08.345. View

Heitmiller R, Marasco W, Hruban R, Marsh B . Endobronchial metastasis. J Thorac Cardiovasc Surg. 1993; 106(3):537-42. View

Pastorino U, Buyse M, Friedel G, Ginsberg R, Girard P, Goldstraw P . Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases. J Thorac Cardiovasc Surg. 1997; 113(1):37-49. DOI: 10.1016/s0022-5223(97)70397-0. View

Timmerman R, Paulus R, Galvin J, Michalski J, Straube W, Bradley J . Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA. 2010; 303(11):1070-6. PMC: 2907644. DOI: 10.1001/jama.2010.261. View

Kang K, Okoye C, Patel R, Siva S, Biswas T, Ellis R . Complications from Stereotactic Body Radiotherapy for Lung Cancer. Cancers (Basel). 2015; 7(2):981-1004. PMC: 4491695. DOI: 10.3390/cancers7020820. View

Oshiro Y, Aruga T, Tsuboi K, Marino K, Hara R, Sanayama Y . Stereotactic body radiotherapy for lung tumors at the pulmonary hilum. Strahlenther Onkol. 2010; 186(5):274-9. DOI: 10.1007/s00066-010-2072-y. View

Unger K, Ju A, Oermann E, Suy S, Yu X, Vahdat S . CyberKnife for hilar lung tumors: report of clinical response and toxicity. J Hematol Oncol. 2010; 3:39. PMC: 2987864. DOI: 10.1186/1756-8722-3-39. View

Rowe B, Boffa D, Wilson L, Kim A, Detterbeck F, Decker R . Stereotactic body radiotherapy for central lung tumors. J Thorac Oncol. 2012; 7(9):1394-9. DOI: 10.1097/JTO.0b013e3182614bf3. View

Katsimbri P, Bamias A, Froudarakis M, Peponis I, Constantopoulos S, Pavlidis N . Endobronchial metastases secondary to solid tumors: report of eight cases and review of the literature. Lung Cancer. 2000; 28(2):163-70. DOI: 10.1016/s0169-5002(99)00134-8. View

10.

Corbin K, Hellman S, Weichselbaum R . Extracranial oligometastases: a subset of metastases curable with stereotactic radiotherapy. J Clin Oncol. 2013; 31(11):1384-90. DOI: 10.1200/JCO.2012.45.9651. View

11.

Coriat R, Diaz O, De La Fouchardiere C, Desseigne F, Negrier S . Endobronchial metastases from colorectal adenocarcinomas: clinical and endoscopic characteristics and patient prognosis. Oncology. 2008; 73(5-6):395-400. DOI: 10.1159/000136794. View

12.

Navarria P, Ascolese A, Tomatis S, Cozzi L, De Rose F, Mancosu P . Stereotactic body radiotherapy (sbrt) in lung oligometastatic patients: role of local treatments. Radiat Oncol. 2014; 9(1):91. PMC: 3999881. DOI: 10.1186/1748-717X-9-91. View

13.

Adebahr S, Collette S, Shash E, Lambrecht M, Le Pechoux C, Faivre-Finn C . LungTech, an EORTC Phase II trial of stereotactic body radiotherapy for centrally located lung tumours: a clinical perspective. Br J Radiol. 2015; 88(1051):20150036. PMC: 4628529. DOI: 10.1259/bjr.20150036. View

14.

Milano M, Chen Y, Katz A, Philip A, Schell M, Okunieff P . Central thoracic lesions treated with hypofractionated stereotactic body radiotherapy. Radiother Oncol. 2009; 91(3):301-6. DOI: 10.1016/j.radonc.2009.03.005. View

15.

Hamamoto Y, Kataoka M, Yamashita M, Shinkai T, Kubo Y, Sugawara Y . Local control of metastatic lung tumors treated with SBRT of 48 Gy in four fractions: in comparison with primary lung cancer. Jpn J Clin Oncol. 2009; 40(2):125-9. DOI: 10.1093/jjco/hyp129. View

16.

Palma D, Haasbeek C, Rodrigues G, Dahele M, Lock M, Yaremko B . Stereotactic ablative radiotherapy for comprehensive treatment of oligometastatic tumors (SABR-COMET): study protocol for a randomized phase II trial. BMC Cancer. 2012; 12:305. PMC: 3433376. DOI: 10.1186/1471-2407-12-305. View

17.

Park H, Harder E, Mancini B, Decker R . Central versus Peripheral Tumor Location: Influence on Survival, Local Control, and Toxicity Following Stereotactic Body Radiotherapy for Primary Non-Small-Cell Lung Cancer. J Thorac Oncol. 2015; 10(5):832-837. DOI: 10.1097/JTO.0000000000000484. View

18.

Singh D, Chen Y, Hare M, Usuki K, Zhang H, Lundquist T . Local control rates with five-fraction stereotactic body radiotherapy for oligometastatic cancer to the lung. J Thorac Dis. 2014; 6(4):369-74. PMC: 3968553. DOI: 10.3978/j.issn.2072-1439.2013.12.03. View

19.

Ricardi U, Filippi A, Guarneri A, Ragona R, Mantovani C, Giglioli F . Stereotactic body radiation therapy for lung metastases. Lung Cancer. 2011; 75(1):77-81. DOI: 10.1016/j.lungcan.2011.04.021. View

20.

Haseltine J, Rimner A, Gelblum D, Modh A, Rosenzweig K, Jackson A . Fatal complications after stereotactic body radiation therapy for central lung tumors abutting the proximal bronchial tree. Pract Radiat Oncol. 2015; 6(2):e27-33. PMC: 4973477. DOI: 10.1016/j.prro.2015.09.012. View